文献速递呼吸衰竭与机械通气心脑血管急症重症综合管理与镇静镇痛

超声辅助导管定向纤溶治疗急性肺栓塞

Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for Acute Pulmonary Embolism.
PubMed 文献 · N Engl J Med · 2026-03-28
一句话结论中危急性肺栓塞患者中,超声辅助导管定向阿替普酶纤溶联合抗凝较单用抗凝降低7天内主要复合终点事件风险(RR 0.39)。

该多国适应性设计试验纳入中危急性肺栓塞患者(右室/左室舒张末内径比≥1.0且肌钙蛋白升高,并至少两项心肺窘迫指标:收缩压≤110 mm Hg、心率≥100次/分或呼吸频率>20次/分),随机接受超声辅助导管定向阿替普酶纤溶联合抗凝(干预组273例)或单用抗凝(对照组271例)。主要终点为7天内肺栓塞相关死亡、心肺失代偿或崩溃、或症状性肺栓塞复发的复合终点,干预组发生11例(4.0%)vs 对照组28例(10.3%)(RR 0.39,95%CI 0.20-0.77,P=0.005),效应主要由心肺失代偿或崩溃风险降低驱动。7天内大出血干预组11例(4.1%)vs 对照组6例(2.2%)(P=0.32),30天内分别为11例(4.1%)vs 8例(3.0%)(P=0.64),无颅内出血。

要点

  • 中危肺栓塞(右室/左室比≥1.0、肌钙蛋白升高、至少两项心肺窘迫指标)患者中,超声辅助导管定向阿替普酶纤溶联合抗凝较单用抗凝降低7天主要复合终点(4.0% vs 10.3%,RR 0.39,95%CI 0.20-0.77)。
  • 主要终点效应主要由心肺失代偿或崩溃风险降低驱动。
  • 7天内大出血干预组4.1% vs 对照组2.2%(P=0.32),30天内4.1% vs 3.0%(P=0.64),无颅内出血。
  • 30天内其他严重不良事件两组间无实质差异。
  • 研究为多国适应性设计试验,结局判定设盲,由Boston Scientific资助(HI-PEITHO,NCT04790370)。

适用人群与场景

  • 中危急性肺栓塞患者,符合右室舒张末内径与左室舒张末内径比值≥1.0且肌钙蛋白升高。
  • 并至少具备两项心肺窘迫指标:收缩压≤110 mm Hg、心率≥100次/分、呼吸频率>20次/分。

诊断标准与关键阈值

  • 中危肺栓塞纳入标准:右室/左室舒张末内径比≥1.0、肌钙蛋白升高、至少两项心肺窘迫指标(收缩压≤110 mm Hg、心率≥100次/分、呼吸频率>20次/分)。

处置流程与药物剂量

  • 干预组:超声辅助导管定向纤溶使用阿替普酶,联合抗凝,按预设治疗方案执行。
  • 对照组:单用抗凝,按预设治疗方案执行。

红旗征与不能漏的情况

  • 心肺失代偿或崩溃为研究主要终点组成部分,干预组风险较对照组降低。

研究设计与关键结果

  • 多国适应性设计试验,意向性治疗人群544例:干预组273例,对照组271例;平均年龄58.2±13.5岁,女性42.6%。
  • 7天内主要复合终点(肺栓塞相关死亡、心肺失代偿或崩溃、症状性肺栓塞复发):干预组11例(4.0%,95%CI 2.3-7.1)vs 对照组28例(10.3%,95%CI 7.2-14.5),RR 0.39(95%CI 0.20-0.77),P=0.005。
  • 效应主要由干预组心肺失代偿或崩溃风险降低驱动。
  • 7天内大出血:干预组11例(4.1%)vs 对照组6例(2.2%),P=0.32;30天内大出血:干预组11例(4.1%)vs 对照组8例(3.0%),P=0.64。
  • 30天内其他严重不良事件两组间无实质差异;无颅内出血发生。

证据类型、等级与局限

  • 研究类型:多国适应性设计试验,结局判定设盲。
  • 资助:Boston Scientific;HI-PEITHO,ClinicalTrials.gov NCT04790370。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于中危急性肺栓塞且符合纳入标准(右室/左室比≥1.0、肌钙蛋白升高、至少两项心肺窘迫指标)的患者,超声辅助导管定向阿替普酶纤溶联合抗凝较单用抗凝降低7天内肺栓塞相关死亡、心肺失代偿或崩溃、症状性复发复合终点风险。
  • 7天内大出血干预组4.1% vs 对照组2.2%(P=0.32),30天内4.1% vs 3.0%(P=0.64),无颅内出血,两组其他严重不良事件无实质差异。

指南或共识出处

  • HI-PEITHO试验,ClinicalTrials.gov NCT04790370。

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Whether anticoagulation alone is an adequate treatment for acute, intermediate-risk pulmonary embolism is uncertain.

METHODS: We conducted a multinational, adaptive-design trial with blinded outcome adjudication. Patients with intermediate-risk pulmonary embolism (with a ratio of right ventricular end-diastolic diameter to left ventricular end-diastolic diameter of ≥1.0 and an elevated troponin level) were eligible if they had at least two indicators of cardiorespiratory distress (systolic blood pressure of ≤110 mm Hg, a heart rate of ≥100 beats per minute, or a respiratory rate of >20 breaths per minute). Patients were randomly assigned to undergo ultrasound-facilitated, catheter-directed fibrinolysis with alteplase plus anticoagulation (the intervention group) or anticoagulation alone (the control group) according to prespecified treatment protocols. The primary outcome was a composite of pulmonary embolism-related death, cardiorespiratory decompensation or collapse, or symptomatic recurrence of pulmonary embolism within 7 days.

RESULTS: The intention-to-treat population comprised 544 patients: 273 in the intervention group and 271 in the control group. The mean (±SD) age was 58.2±13.5 years, and 42.6% of the patients were women. A primary-outcome event occurred in 11 patients (4.0%; 95% confidence interval [CI], 2.3 to 7.1) in the intervention group and 28 (10.3%; 95% CI, 7.2 to 14.5) in the control group (relative risk, 0.39; 95% CI, 0.20 to 0.77; P = 0.005). The effect was driven primarily by a lower risk of cardiorespiratory decompensation or collapse in the intervention group. Major bleeding occurred within 7 days after randomization in 11 patients (4.1%) in the intervention group and 6 (2.2%) in the control group (P = 0.32); major bleeding occurred within 30 days in 11 patients (4.1%) and 8 patients (3.0%), respectively (P = 0.64). No substantial between-group differences in the incidence of other serious adverse events were observed up to 30 days after randomization; no intracranial hemorrhage occurred.

CONCLUSIONS: In patients with acute, intermediate-risk pulmonary embolism, ultrasound-facilitated, catheter-directed fibrinolysis plus anticoagulation led to a lower risk of the composite of pulmonary embolism-related death, cardiopulmonary decompensation or collapse, or symptomatic recurrence of pulmonary embolism within 7 days than anticoagulation alone. (Funded by Boston Scientific; HI-PEITHO ClinicalTrials.gov number, NCT04790370.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Rosenfield K, Klok FA, Piazza G, et al. Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for Acute Pulmonary Embolism. N Engl J Med. 2026. PMID: 41910345. doi:10.1056/NEJMoa2516567

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。